Trial Profile
A Study Investigating the Tolerance and Efficacy of Pimavanserin for Psychotic Symptoms in Patients With Parkinsonism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2018
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinsonian disorders; Psychotic disorders
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2018 New trial record
- 13 Jul 2018 Results published in the Clinical Neuropharmacology.